Publications [#63228] of Mark W. Dewhirst

Papers Published

1. Page, R.L. and Thrall, D.E. and George, S.L. and Price, G.S. and Heidner, G.L. and McEntee, M.C. and Novotney, C.A. and Hauck, M.L. and Dewhirst, M.W., Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs, Int. J. Hyperth. (UK), vol. 8 no. 6 (1992), pp. 761 - 9
   (last updated on 2007/04/14)

   Abstract:
   A statistical method for estimating clinical toxicity was used to determine a theoretical isoeffect dose-modifying factor for dogs with disseminated or refractory neoplasia treated with cis-diammine dichloroplatinum (II) plus whole-body hyperthermia or CDDP alone. CDDP was administered every 3 weeks with vigorous saline hydration to 54 dogs (CDDP alone n=21, CDDP/WBH n=33) that were eligible for entry into this non-randomized study. CDDP was administered during the plateau phase of WBH in dogs receiving combined therapy. Acute toxicity included myelosuppression (CDDP n=7; CDDP/WBH n=5), nephrotoxicity (CDDP n=1, CDDP/WBH n=1) and respiratory distress (CDDP/WBH n=2). Eight dogs experienced chronic renal dysfunction as a result of CDDP (n=2) or CDDP/WBH (n=6). A theoretical thermal dose-modifying factor was determined for both acute and cumulative toxicity by comparing the maximum tolerated dose (MTD) of each treatment group. The MTD (±.standard error) of CDDP/WBH for acute toxicity only was 54.6 (4.3) mg/M² and for CDDP alone the MTD was 73.6 (40) mg/M². Thus, the isoeffect dose-modifying factor for acute toxicity was 1.35 (0.12). The MTD (SE) of CDDP/WBH for cumulative toxicity (acute plus chronic toxicity) was 46.4 (2.7) mg/M² and for CDDP alone was 70.0 (2.9) mg/M²

   Keywords:
   biothermics;